Philip Bonomi to Adenocarcinoma
This is a "connection" page, showing publications Philip Bonomi has written about Adenocarcinoma.
Connection Strength
1.312
-
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
Score: 0.405
-
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
Score: 0.123
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.113
-
Alteration of integrated optical density and intercellular structure after induction chemotherapy and survival in lung carcinoma patients treated surgically. Anal Quant Cytol Histol. 1994 Feb; 16(1):18-24.
Score: 0.108
-
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 2013 Jul 16; 12:76.
Score: 0.104
-
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
Score: 0.100
-
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21.
Score: 0.098
-
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
Score: 0.058
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.036
-
Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
Score: 0.027
-
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):247-52.
Score: 0.022
-
Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
Score: 0.021
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
Score: 0.017
-
Hormone receptor studies in axillary metastases from occult breast cancers. Cancer. 1987 Mar 15; 59(6):1170-2.
Score: 0.017
-
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83.
Score: 0.016
-
Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresis. Prostate. 1985; 6(3):315-23.
Score: 0.014
-
Provisional "normograms" for identifying adenocarcinomas of the prostate or colon and hepatocellular carcinoma derived from their distribution of proteins separated by two-dimensional electrophoresis. Prostate. 1983; 4(1):83-9.
Score: 0.013
-
A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
Score: 0.010
-
Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92.
Score: 0.005
-
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
Score: 0.005